ReviewBiomolecules2023
Combination Drug Therapy for the Management of Chronic Neuropathic Pain.
Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- The effect of pregabalin on pain and function in knee osteoarthritis: a systematic review and meta-analysis of randomized controlled trials.Inflammopharmacology · 2026Pooled it
- The effect of different transcranial magnetic stimulation protocols on pain scores in patients with neuropathic pain: a systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Hydrogen-Rich Water Enhances Ibuprofen-Induced Antinociception and Modulates NOX Signaling and the NLRP3 Inflammasome in Chronic Inflammatory Pain.International journal of molecular sciences · 2026Article
- Multicomponent Oxicam-Metformin Salts: Toward a Strategy for Enhancing Solubility and Stability.Crystal growth & design · 2026Article
- Neuroimaging-Guided Insights into the Molecular and Network Mechanisms of Chronic Pain and Neuromodulation.International journal of molecular sciences · 2026Review
- Treatment of neuropathic pain in diabetic rats with synergistic combinations of nortriptyline + tramadol and nortriptyline + ibuprofen.Frontiers in pharmacology · 2026Article
- Centrally Acting Skeletal Muscle Relaxants Sharing Molecular Targets with Drugs for Neuropathic Pain Management.Brain sciences · 2025Review
- Endothelin-Converting Enzyme-Like 1 Regulated by LIF Contributes to Chronic Constriction Injury-Induced Neuropathic Pain in Mice.CNS neuroscience & therapeutics · 2025Article
- Metabolic and Hormonal Changes in Pediatric Burn Patients: Mechanisms, Evidence, and Care Strategies.European burn journal · 2025Review
- Neuropathic Pain: A Comprehensive Bibliometric Analysis of Research Trends, Contributions, and Future Directions.Current pain and headache reports · 2025Review
- Trends in Mixed Pain Research Over Three Decades (1993-2024): A Bibliometric Analysis.Current pain and headache reports · 2025Review
- Application of a Nociceptive Test Battery to Assess Potential Synergy between Two Analgesics in Healthy Subjects.ACS pharmacology & translational science · 2025Article
- Article
- Practice and application of learning curve theory in improving prescription review skills in standardized training for pharmacists in medical institutions.Scientific reports · 2025Article
- Mesenchymal stem cells as a therapeutic strategy to combat oxidative stress-mediated neuropathic pain.BioImpacts : BI · 2025Review
- Advances in Neuroimaging of Breast Cancer Pain: An Overview.Journal of pain research · 2025Review
- Review
- PDCD4 inhibition alleviates neuropathic pain by regulating spinal autophagy and neuroinflammation.Molecular painArticle
- Combination of GABA-derived short peptides and pregabalin in neuropathic pain: In vivo and in silico evaluation.Molecular painArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic neuropathic pain (NP) is an increasingly prevalent disease and leading cause of disability which is challenging to treat. Several distinct classes of drugs are currently used for the treatment of chronic NP, but each drug targets only narrow components of the underlying pathophysiological mechanisms, bears limited efficacy, and comes with dose-limiting side effects. Multimodal therapies have been increasingly proposed as potential therapeutic approaches to target the multiple mechanisms underlying nociceptive transmission and modulation. However, while preclinical studies with combination therapies showed promise to improve efficacy over monotherapy, clinical trial data on their efficacy in specific populations are lacking and increased risk for adverse effects should be carefully considered. Drug-drug co-crystallization has emerged as an innovative pharmacological approach which can combine two or more different active pharmaceutical ingredients in a single crystal, optimizing pharmacokinetic and physicochemical characteristics of the native molecules, thus potentially capitalizing on the synergistic efficacy between classes of drugs while simplifying adherence and minimizing the risk of side effects by reducing the doses. In this work, we review the current pharmacological options for the treatment of chronic NP, focusing on combination therapies and their ongoing developing programs and highlighting the potential of co-crystals as novel approaches to chronic NP management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.